N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial
Open Access
- 24 June 2013
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 24 (10) , 2548-2554
Abstract
Based on preclinical studies, the vascular endothelial pathway is an important mechanism for estrogen receptor resistance. We conducted a phase II study of fulvestrant and bevacizumab in patients with aromatase inhibitor pretreated metastatic breast cancer. A single-stage phase II study was conducted with these objectives: 6-month progression-free survival (PFS), tumor response, toxic effect, and overall survival. Regimen: 250 mg fulvestrant days 1 and 15 (cycle 1) then day 1 (cycle 2 and beyond) and 10 mg/kg bevacizumab days 1 and 15 of each 4-week cycle. At interim analysis, 20 eligible patients initiated treatment, 11 were progression free and on treatment at 3 months, not meeting the protocol-specified efficacy requirements (at least 12 of 20). Accrual remained open during interim analysis with 36 patients enrolling before final study closure. Among the 33 eligible patients, the median PFS was 6.2 months [95% confidence interval (CI) 3.6–10.1 months]. Of the 18 with measurable disease, 4 (22%) patients (95% CI 6% to 48%) had a confirmed tumor response (1 complete, 3 partial). The most common grade 3/4 adverse events were hypertension 3 (9%) and headache 3 (9%). The fulvestrant/bevacizumab combination is safe and tolerable; however, it did not meet its statistical end point.Keywords
Funding Information
- Genentech
- Breast Cancer Research Foundation
- National Institute of Health (CA25224)
This publication has 25 references indexed in Scilit:
- FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast CancerJournal of Clinical Oncology, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast CancerJournal of Clinical Oncology, 2011
- FulvestrantDrugs, 2011
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast CancerJournal of Clinical Oncology, 2010
- Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trialsCritical Reviews in Oncology/Hematology, 2010
- Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic reviewBreast Cancer Research and Treatment, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormonesEndocrine-Related Cancer, 2006
- Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin releaseMolecular and Cellular Endocrinology, 2005